Published in:
18-11-2023 | Liver Transplantation | Original Article
Serial circulating tumor DNA profiling predicts tumor recurrence after liver transplantation for liver cancer
Authors:
Ao Huang, De-Zhen Guo, Xuan Zhang, Ying Sun, Shi-Yu Zhang, Xin Zhang, Xiu-Tao Fu, Yu-Peng Wang, Guo-Huan Yang, Qi-Man Sun, Yi-Feng He, Kang Song, Xiao-Wu Huang, Xin-Rong Yang, Wei-Ren Liu, Zhen-Bin Ding, Ying-Hong Shi, Jia Fan, Jian Zhou
Published in:
Hepatology International
|
Issue 1/2024
Login to get access
Abstract
Background
Minimal residual disease (MRD) is proposed to be responsible for tumor recurrence. The role of circulating tumor DNA (ctDNA) to detect MRD, monitor recurrence, and predict prognosis in liver cancer patients undergoing liver transplantation (LT) remains unrevealed.
Methods
Serial blood samples were collected to profile ctDNA mutational changes. Baseline ctDNA mutational profiles were compared with those of matched tumor tissues. Correlations between ctDNA status and recurrence rate (RR) and recurrence-free survival (RFS) were analyzed, respectively. Dynamic change of ctDNA was monitored to predict tumor recurrence.
Results
Baseline mutational profiles of ctDNA were highly concordant with those of tumor tissues (median, 89.85%; range 46.2–100%) in the 74 patients. Before LT, positive ctDNA status was associated with higher RR (31.7% vs 11.5%; p = 0.001) and shorter RFS than negative ctDNA status (17.8 vs 19.4 months; p = 0.019). After LT, the percentage of ctDNA positivity decreased (17.6% vs 47.0%; p < 0.001) and patients with positive ctDNA status had higher RR (46.2% vs 21.3%; p < 0.001) and shorter RFS (17.2 vs 19.2 months; p = 0.010). Serial ctDNA profiling demonstrated patients with decreased or constant negative ctDNA status had lower RR (33.3% vs 50.0%; p = 0.015) and favorable RFS (18.2 vs 15.0 months, p = 0.003) than those with increased or constant positive ctDNA status. Serial ctDNA profiling predicted recurrence months ahead of imaging evidence and serum tumor biomarkers.
Conclusions
ctDNA could effectively detect MRD and predict tumor recurrence in liver cancer patients undergone LT.